(Q65395942)
Statements
A Phase 1/2, Single-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Study of Subcutaneously Administered ALN-GO1 in Healthy Adult Subjects, and Patients With Primary Hyperoxaluria Type 1 (English)
0 references
8 March 2016
0 references
23 January 2019
0 references
52
0 references
6 year
0 references
64 year
0 references